TABLE 4.
Comparison of incidences of lamivudine-resistance-associated mutations between patients chronically infected with HBV/B2 (n = 550) and HBV/C2 (n = 3,404)
| HBV subgenotype | Mutation incidence (%) |
|||||||
|---|---|---|---|---|---|---|---|---|
| Total | M204I | M204V | M204I + V | L80I | V173L | L180M | M204I + CMa | |
| B2 | 19.8 | 10.0 | 8.7 | 1.1 | 5.3 | 0 | 10.2 | 8.6 |
| C2 | 27.9 | 15.5 | 10.3 | 2.1 | 8.2 | 3.8 | 19.0 | 18.7 |
| P | <0.01 | <0.01 | 0.26 | 0.09 | 0.02 | <0.01 | <0.01 | <0.01 |
a
CM, compensatory mutation. The proportions of M204I + CM (with any of L80I, V173L, and L180M) in all M204I-positive samples are 43.6% for HBV/B2 and 67.2% for HBV/C2 (P < 0.01).